SG11201702185UA - PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS - Google Patents
PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTSInfo
- Publication number
- SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA
- Authority
- SG
- Singapore
- Prior art keywords
- intermediates
- processes
- preparation
- c5ar antagonists
- c5ar
- Prior art date
Links
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462057107P | 2014-09-29 | 2014-09-29 | |
PCT/US2015/052697 WO2016053890A1 (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201702185UA true SG11201702185UA (en) | 2017-04-27 |
Family
ID=55583729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201702185UA SG11201702185UA (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Country Status (19)
Country | Link |
---|---|
US (5) | US9745268B2 (pt) |
EP (2) | EP3682879B1 (pt) |
JP (1) | JP6898229B6 (pt) |
KR (2) | KR102593431B1 (pt) |
CN (2) | CN113121415A (pt) |
AU (2) | AU2015324111B2 (pt) |
BR (1) | BR112017006232B1 (pt) |
CA (2) | CA3220371A1 (pt) |
DK (1) | DK3200791T3 (pt) |
ES (2) | ES2926828T3 (pt) |
IL (1) | IL251061B (pt) |
MA (1) | MA52308A (pt) |
MX (2) | MX368492B (pt) |
NZ (2) | NZ730123A (pt) |
PL (1) | PL3200791T3 (pt) |
PT (1) | PT3200791T (pt) |
RU (1) | RU2712233C2 (pt) |
SG (1) | SG11201702185UA (pt) |
WO (1) | WO2016053890A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101680818B1 (ko) | 2008-12-22 | 2016-11-29 | 케모센트릭스, 인크. | C5ar 길항제 |
WO2011163640A1 (en) | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
SG11201702185UA (en) * | 2014-09-29 | 2017-04-27 | Chemocentryx Inc | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
WO2019089468A1 (en) * | 2017-10-30 | 2019-05-09 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
MA52808A (fr) | 2018-06-07 | 2021-04-14 | Chemocentryx Inc | Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca |
MA54318B1 (fr) | 2018-11-30 | 2023-08-31 | Chemocentryx Inc | Formulations de capsules |
KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
CN113957106B (zh) * | 2021-11-03 | 2024-04-19 | 暨明医药科技(苏州)有限公司 | 一种Avacopan及其中间体的制备方法 |
CN114262291B (zh) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | 一种阿伐可泮的合成方法 |
WO2023158722A2 (en) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
MXPA01002173A (es) | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
RU2197288C2 (ru) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
AU2001259511A1 (en) | 2000-05-05 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
JP2004502672A (ja) * | 2000-06-29 | 2004-01-29 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症剤および免疫抑制剤としてのアリールフェニルシクロプロピルスルフィド誘導体およびその使用 |
US7105567B2 (en) | 2000-08-10 | 2006-09-12 | Mitsubishi Pharma Corporation | 3-substituted urea derivatives and medicinal use thereof |
KR100884709B1 (ko) | 2000-09-14 | 2009-02-19 | 미쓰비시 타나베 파마 코퍼레이션 | 신규한 아미드 유도체의 광학 활성체 및 그의 의약적 용도 |
JP5260818B2 (ja) | 2000-09-29 | 2013-08-14 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | 高親和性低分子C5a受容体調節物質 |
SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
DE10293174D2 (de) | 2001-07-19 | 2004-07-01 | Luk Lamellen & Kupplungsbau | Übertragungsstrecke zum Ansteuern einer Kupplung |
ATE360441T1 (de) | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
ATE424393T1 (de) | 2001-09-21 | 2009-03-15 | Mitsubishi Tanabe Pharma Corp | 3-substituierte 4-pyrimidonderivate |
ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
AU2003218374A1 (en) | 2002-03-28 | 2003-10-13 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
EP1490044A4 (en) | 2002-03-29 | 2008-04-16 | Neurogen Corp | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
WO2004018460A1 (en) | 2002-08-21 | 2004-03-04 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2003290605A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
MXPA06014574A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Piperidinas n-sustituidas y su uso como farmaceuticos. |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
BRPI0607756A2 (pt) | 2005-02-18 | 2010-05-18 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
DK1951663T3 (en) | 2005-11-24 | 2016-10-10 | Dompé Farm S P A | (r)-arylkylaminoderivater og farmaceutiske sammensætninger indeholdende dem |
AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
WO2008053270A2 (en) | 2006-10-31 | 2008-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
KR20100027241A (ko) | 2007-06-29 | 2010-03-10 | 토렌트 파마슈티칼스 리미티드 | Hsp 인듀서로서 신규의 치환된 피페리돈 |
CA2737219C (en) | 2008-08-11 | 2017-02-28 | Tracy Keller | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
EP2331561A4 (en) | 2008-09-03 | 2013-02-27 | Xenome Ltd | PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME |
US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
KR101680818B1 (ko) | 2008-12-22 | 2016-11-29 | 케모센트릭스, 인크. | C5ar 길항제 |
US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
WO2011163640A1 (en) | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
AU2013277154A1 (en) | 2012-06-20 | 2014-12-18 | Jonathan E. Grob | Complement pathway modulators and uses thereof |
WO2014180961A1 (en) | 2013-05-08 | 2014-11-13 | Novo Nordisk A/S | Use of c5ar antagonists |
SG11201702185UA (en) * | 2014-09-29 | 2017-04-27 | Chemocentryx Inc | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
EP3439658B1 (en) | 2016-04-04 | 2021-11-24 | ChemoCentryx, Inc. | Soluble c5ar antagonists |
CA3205474A1 (en) | 2020-12-21 | 2022-06-30 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
-
2015
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/pt active IP Right Grant
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/ko active IP Right Grant
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/en active Application Filing
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/ko active Application Filing
- 2015-09-28 ES ES20160995T patent/ES2926828T3/es active Active
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/ru active
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 PT PT158456103T patent/PT3200791T/pt unknown
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/da active
- 2015-09-28 PL PL15845610T patent/PL3200791T3/pl unknown
- 2015-09-28 ES ES15845610T patent/ES2802428T3/es active Active
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/ja active Active
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/zh active Pending
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 MA MA052308A patent/MA52308A/fr unknown
- 2015-09-28 CA CA3220371A patent/CA3220371A1/en active Pending
- 2015-09-28 MX MX2017003789A patent/MX368492B/es active IP Right Grant
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/en active Active
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/en active Active
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/zh active Active
- 2015-09-28 CA CA2960733A patent/CA2960733C/en active Active
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/es unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251061A0 (en) | Processes and building materials in the preparation of c5ar antagonists | |
IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
IL251868B (en) | Anti-tim3 antibodies and methods of use | |
GB201421847D0 (en) | Dispensers and methods of use thereof | |
IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
IL247754A0 (en) | Antibodies against mcam and related methods of use | |
IL247315A0 (en) | Anti-acth antibodies and their uses | |
HK1250146A1 (zh) | 抗前-bcr拮抗劑和方法 | |
IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
ZA201604870B (en) | Recombinant microorganisms and methods of use thereof | |
HK1246288A1 (zh) | S1pr2拮抗劑及其用途 | |
IL247448A0 (en) | Peptides and methods of use | |
GB201509977D0 (en) | Dispensers and methods of use thereof | |
PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
GB201404133D0 (en) | Garment and method of use thereof |